In this article, we will be taking a look at the 12 cheap foods with anti-aging properties that longevity scientists swear by. If you do not want to learn about the anti-aging trends, head straight to 5 Cheap Foods With Anti-Aging Properties That Longevity Scientists Swear By. Anti-Aging Trends: Market Insights & Emerging Solutions Anti-aging […]

CARLSBAD, Calif., April 01, 2024--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the appointment of veteran industry executive Charlotte Hubbert, Ph.D., as Vice President of Corporate Development. Dr. Hubbert has an extensive background in cell therapy research and venture investment across a broad range of therapeutic modalities and development stages, and has a

In this article, we will be taking a look at the 15 best anti-aging foods for youthful skin. If you do not want to learn about the anti-aging trends and superfoods markets, head straight to the 5 Best Anti-Aging Foods for Youthful Skin. Achieving youthful, radiant skin is a goal many aspire to, and a […]

CARLSBAD, Calif., March 18, 2024--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, and the Christopher & Dana Reeve Foundation, a non-profit organization dedicated to advancing innovative research and improving quality of life for individuals impacted by paralysis, are proud to again collaborate to present the 2nd Annual Spinal Cord Injury Investor Symposium ("2nd SCIIS"). The 2nd

In this article, we will take a detailed look at Billionaire Ken Fisher and Corporate Insiders Are Buying These 10 Stocks. For a quick overview of such stocks, read our article Billionaire Ken Fisher and Corporate Insiders Are Buying These 5 Stocks. Stocks wobbled on Thursday after a hotter-than-expected PPI report confirmed fears that inflation […]

CARLSBAD, Calif., March 13, 2024--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that 24 month results from patients enrolled in a Phase 1/2a clinical study (ClinicalTrials.gov Identifier: NCT02286089) of RG6501 (OpRegen) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD), will be presented at the 2024 Retinal Cell & Gene

CARLSBAD, Calif., March 11, 2024--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that preclinical results as part of a surgical development study evaluating the survival and distribution of RG6501 (OpRegen) will be presented at the 2024 Association for Research in Vision and Ophthalmology Annual Meeting (2024 ARVO). The meeting will be held May 5-9, 2024, in Seatt

Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q4 2023 Earnings Call Transcript March 7, 2024 Lineage Cell Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to the Lineage Cell Therapeutics Fourth Quarter and Fiscal Year-End 2023 Conference Call. At […]

Lineage Cell Therapeutics Inc. (LCTX) Announces Financial Outcomes and Business Progress

CARLSBAD, Calif., March 07, 2024--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its fourth quarter and full year 2023 financial and operating results and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and provide a business update.